Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network

Cancer Research

Volumn 73, Issue 12, 2013, Pages 3511-3524

  Vera, Julio ^a,c   Schmitz, Ulf ^a   Lai, Xin ^a,d   Engelmann, David ^b   Khan, Faiz M ^a   Wolkenhauer, Olaf ^a,e   Pützer, Brigitte M ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ERLOTINIB; LAPATINIB; MICRORNA 205; PROTEIN P73; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL; CANCER RESISTANCE; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; EXPERIMENTAL STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MATHEMATICAL COMPUTING; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ALGORITHMS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; COMPUTER SIMULATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; KINETICS; MICRORNAS; MODELS, GENETIC; NEOPLASMS; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

EID: 84879088218     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4095     Document Type: Article

References (50)

1. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10.
2. Stanelle J, Pützer BM. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol Med 2006;12:177-85.
3. Blattner C, Sparks A, Lane D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol Cell Biol 1999;19:3704-13. (Pubitemid 29193830)
4. Engelmann D, Pützer BM. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance. Drug Resist Updat 2010;13:119-31.
5. Rödicker F, Stiewe T, Zimmermann S, Pützer BM. Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res 2001;61:7052-5. (Pubitemid 32946495)
6. Stiewe T, Pützer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000;26:464-9.
7. Chung J, Irwin MS. Targeting the p53-family in cancer and chemosensitivity: triple threat. Curr Drug Targets 2010;11:667-81.
8. Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, et al. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin. Cancer Res 2008;14:82-8. (Pubitemid 351409260)
9. Han S, Park K, Bae B-N, Kim KH, Kim H-J, Kim Y-D, et al. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res Treat 2003;82:11-6. (Pubitemid 37476014)
10. Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M, et al. E2F1 in melanoma progression and metastasis. J Natl Cancer Inst 2010;102:127-33.
11. Pützer BM, Tuve S, Tannapfel A, Stiewe T. Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN′-p73 transcript. Cell Death Differ 2003;10:612-4. (Pubitemid 36656651)
12. Stiewe T, Zimmermann S, Frilling A, Esche H, Pützer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 2002;62:3598-602.
13. Tuve S, Wagner SN, Schittek B, Pützer BM. Alterations of DeltaTA-p73 splice transcripts during melanoma development and progression. Int J Cancer 2004;108:162-6. (Pubitemid 37444460)
14. Emmrich S, Wang W, John K, Li W, Pützer BM. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Mol Cancer 2009;8:61.
15. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012;11:3067-78.
16. Engelmann D, Pützer BM. The dark side of E2F1: in transit beyond apoptosis. Cancer Res 2012;72:571-5.
17. Vera J, Wolkenhauer O. A system biology approach to understand functional activity of cell communication systems. Methods Cell Biol 2008;90:399-415.
18. Vera J, Rath O, Balsa-Canto E, Banga JR, Kolch W, Wolkenhauer O. Investigating dynamics of inhibitory and feedback loops in ERK signalling using power-law models. Mol Biosyst 2010;6:2174-91.
19. Inohara N, Ding L, Chen S, Núñez G. harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 1997;16:1686-94. (Pubitemid 27151963)
20. Zhu S, Belkhiri A, El-Rifai W. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to ge fitinib. Gastroenterology 2011;141:1738-48. e1-2.
21. Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011;17:2350-60.
22. Engelmann D, Knoll S, Ewerth D, Steder M, Stoll A, Pützer BM. Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death. Cell Mol Life Sci 2010;67:931-48.
23. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 2004;279:8076-83. (Pubitemid 38294697)
24. Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci USA 2008;105:19678-83.
25. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009;69:2287-95.
26. Wu H, Zhu S, Mo Y-Y. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 2009;19:439-48.
27. Frolov A, Schuller K, Tzeng C-WD, Cannon EE, Ku BC, Howard JH, et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther 2007;6:548-54. (Pubitemid 47328329)
28. Buhlmann S, Pützer BM. DNp73 a matter of cancer: mechanisms and clinical implications. Biochim Biophys Acta 2008;1785:207-16.
29. Guan M, Chen Y. Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol 2005;58:1175-9. (Pubitemid 41566462)
30. Massagué J. TGFbeta in Cancer. Cell 2008;134:215-30.
31. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm A-V, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009;114:263-75.
32. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 2011;108:5021-6.
33. González-García I, Solé RV, Costa J. Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci USA 2002;99:13085-9.
34. Yao G, Lee TJ, Mori S, Nevins JR, You L. A bistable Rb-E2F switch underlies the restriction point. Nat. Cell Biol 2008;10:476-82.
35. Zhang X-P, Liu F, Wang W. Coordination between cell cycle progression and cell fate decision by the p53 and E2F1 pathways in response to DNA damage. J Biol Chem 2010;285:31571-80.
36. Wong JV, Yao G, Nevins JR, You L. Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC. Mol Cell 2011;41:275-85.
37. Katoh Y, Katoh M. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med 2008;22:271-5.
38. Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011;128:1327-34.
39. Castillo J, Goñi S, Latasa MU, Perugorría MJ, Calvo A, Muntané J, et al. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. Gastroenterology 2009;137:1805-15.e1-4.
40. Samavarchi-Tehrani P, Golipour A, David L, Sung H-K, Beyer TA, Datti A, et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010;7:64-77.
41. Bryant JL, Britson J, Balko JM, Willian M, Timmons R, Frolov A, et al. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br J Cancer 2012;106:148-56.
42. Lai X, Schmitz U, Gupta SK, Bhattacharya A, Kunz M, Wolkenhauer O, et al. Computational analysis of target hub gene repression regulated by multiple and cooperative miRNAs. Nucleic Acids Res 2012;40:8818-34.
43. Li Y, Li Y, Zhang H, Chen Y. MicroRNA-mediated positive feedback loop and optimized bistable switch in a cancer network Involving miR-17-92. PLoS ONE 2011;6:e26302.
44. Merlo LMF, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924-35. (Pubitemid 44862677)
45. Iwasa Y, Nowak MA, Michor F. Evolution of resistance during clonal expansion. Genetics 2006;172:2557-66.
46. Gatenby RA, Brown J, Vincent T. Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res 2009;69:7499-502.
47. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009;9:738-48.
48. Marin JJG, Briz O, Monte MJ, Blazquez AG, Macias RIR. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr. Cancer Drug Targets 2012;12:402-38.
49. Mangan S, Alon U. Structure and function of the feed-forward loop network motif. Proc Natl Acad Sci U S A 2003;100:11980-5. (Pubitemid 37271501)
50. Nakagawa T, Takahashi M, Ozaki T, Watanabe K-I, Todo S, Mizuguchi H, et al. Autoinhibitory regulation of P73 by DNp73 to modulate cell survival and death through a P73-specific target element within the DNp73 promoter. Mol Cell Biol 2002;22:2575-85. (Pubitemid 34262980)